Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
- Conditions
- Interventions
- Biological: Axicabtagene CiloleucelDrug: FludarabineDrug: CyclophosphamideDrug: LevetiracetamDrug: TocilizumabDrug: DexamethasoneDrug: DoxorubicinDrug: High-dose methylprednisoloneDrug: PrednisoneDrug: BendamustineDrug: VincristineDrug: RituximabDrug: IfosfamideDrug: CarboplatinDrug: MethylprednisoloneDrug: EtoposideDrug: GemcitabineDrug: OxaliplatinDrug: Cisplatin
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 307
- Registration Number
- NCT02348216
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦Princess Margaret, Toronto, Ontario, Canada
Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02345863
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients
- Conditions
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Munich Municipal Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT02320383
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02320487
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States
🇺🇸San Juan Oncology Associates, Farmington, New Mexico, United States
Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 331
- Registration Number
- NCT02257567
- Locations
- 🇳🇱
UMC St. Radboud; Hematology, Nijmegen, Netherlands
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Swedish Cancer Inst., Seattle, Washington, United States
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Brown University
- Target Recruit Count
- 11
- Registration Number
- NCT02257242
- Locations
- 🇺🇸
Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island, United States
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 20
- Registration Number
- NCT02240719
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2019-09-13
- Target Recruit Count
- 24
- Registration Number
- NCT02224729
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02194374
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.